12 completed, 1 not yet recruiting, 1 recruiting, 1 unknown. 15 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 12, Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 2 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
Follow Testosterone Propionate: new trials by email Literature Review of Testosterone Propionate trials Research Report on Testosterone Propionate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism Testosterone enanthate - Hypogonadism, Male | Phase 3 | Recruiting | Halozyme Therapeutics | 100 | 2025-03-07 | 2026-11-06 |
| Use of Testosterone to Prevent Post-Surgical Muscle Loss - Pilot Study Aveed 750 MG in 3 ML IM Injection, Normal Saline 3 ML IM Injection - Muscle Atrophy, Surgery | Phase 2 / Phase 3 | Unknown | The Stone Research Foundation for Sports Medicine and Arthritis | 15 | 2020-05-08 | 2021-08-31 |
| Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men LPCN 1021 - Hypogonadism, Male | Phase 3 | Completed | Lipocine Inc. | 138 | 2018-04-30 | 2021-06-10 |
| Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021) LPCN 1021 - Hypogonadism, Male | Phase 3 | Completed | Lipocine Inc. | 100 | 2017-01-01 | 2019-10-23 |
| Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021). LPCN 1021 - Hypogonadism, Male | Phase 3 | Completed | Lipocine Inc. | 95 | 2016-12-01 | 2019-10-23 |
| Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism Oral testosterone undecanoate, LPCN 1021, Topical testosterone gel 1.62 % - Male Hypogonadism | Phase 3 | Completed | Lipocine Inc. | 315 | 2014-02-01 | 2017-10-23 |
| A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy Testosterone Solution, Placebo Solution - Hypogonadism | Phase 3 | Completed | Eli Lilly and Company | 715 | 2013-05-01 | 2015-12-28 |
| A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations Testosterone MD-Lotion - Hypogonadism | Phase 3 | Completed | Eli Lilly and Company | 71 | 2008-10-01 | 2011-01-05 |
| A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations Testosterone MD-Lotion - Hypogonadism | Phase 3 | Completed | Eli Lilly and Company | 155 | 2008-06-01 | 2011-07-25 |
| Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women testosterone gel, placebo gel - Hypoactive Sexual Desire Disorder | Phase 3 | Completed | BioSante Pharmaceuticals | 575 | 2008-03-01 | 2013-01-10 |
| Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women testosterone gel, placebo gel - Hypoactive Sexual Desire Disorder | Phase 3 | Completed | BioSante Pharmaceuticals | 3656 | 2008-01-01 | 2021-10-29 |
| Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women testosterone gel, placebo gel - Hypoactive Sexual Desire Disorder | Phase 3 | Completed | BioSante Pharmaceuticals | 597 | 2006-12-01 | 2013-01-10 |
| Low-Dose Testosterone in Improving Libido in Postmenopausal Female Cancer Survivors therapeutic testosterone, placebo - Cancer Survivor, Sexual Dysfunction | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 150 | 2004-04-01 | 2016-07-13 |
| Testosterone Replacement Therapy in Chronic Spinal Cord Injury Testosterone Transdermal System (Androderm 5 mg patch) - Spinal Cord Injury, Hypogonadism | Phase 2 / Phase 3 | Completed | VA Office of Research and Development | 31 | 2003-08-01 | 2017-11-01 |
Hypogonadism (6) · Eunuchism (5) · Sexual Dysfunctions, Psychological (3) · Breast Neoplasms (1) · Disease (1) · Endocrine System Diseases (1) · Gonadal Disorders (1) · Knee Injuries (1) · Muscular Atrophy (1) · Prostatic Neoplasms (1) · Sexual Dysfunction, Physiological (1) · Sexuality (1) · Spinal Cord Injuries (1) · Wounds and Injuries (1)
Lipocine Inc. (4) · BioSante Pharmaceuticals (3) · Eli Lilly and Company (3) · Alliance for Clinical Trials in Oncology (1) · ECOG-ACRIN Cancer Research Group (1) · Halozyme Therapeutics (1) · The Stone Research Foundation for Sports Medicine and Arthritis (1) · VA Office of Research and Development (1)
United States (11) · Canada (4) · Germany (2) · United Kingdom (2) · Argentina (1) · Australia (1) · France (1) · Italy (1) · Puerto Rico (1) · South Korea (1) · Spain (1) · Sweden (1)
Anthony DelConte, MD (3) · Michael C Snabes, MD, PhD (3) · Anthony Delconte, MD (1) · Charles L. Loprinzi, MD (1) · Mani Vessal, Ph.D. (1) · Michael Schweizer (1) · William Bauman, MD (1)
PMID 17470735, PMID 21252493, PMID 21689131, PMID 21717386, PMID 22172433, PMID 23343764, PMID 24968251, PMID 26498057, PMID 26549704, PMID 34191621, PMID 34994093, PMID 38224135, PMID 39252657
U10CA180820 (1)